Patents Examined by Nicole Kinsey White
  • Membrane lipid coated nanoparticles and method of use
    Patent number: 11471420
    Abstract: Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: October 18, 2022
    Assignee: Coastar Therapeutics Inc.
    Inventor: Eddie Yocon Chung
  • Modified PEDV spike protein
    Patent number: 11464852
    Abstract: The present invention relates to a nucleic acid molecule encoding a modified porcine epidemic diarrhea virus (PEDV) spike (S) protein and the PEDV (S) protein thereof. Further, the present invention relates to immunogenic compositions comprising said modified PEDV spike protein and methods for immunizing a subject comprising the administration of said immunogenic composition to a subject.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: October 11, 2022
    Inventors: Veljko Nikolin, Andreas Gallei
  • Sustained release cowpea mosaic virus or virus-like particle therapeutic constructs for the treatment of cancer
    Patent number: 11433123
    Abstract: A method of treating cancer in a subject in need thereof includes administering in situ to cancer cells of the subject a nanoparticle construct that includes a plurality of cowpea mosaic virus or virus-like particles electrostatically coupled to a plurality of G4 dendrimers having a different surface charge than the cowpea mosaic virus or virus-like particles. The nanoparticle construct upon delivery to a subject can provide a sustained release of the cowpea mosaic virus or virus-like particles and/or G4 dendrimers to a cell or tissue of the subject. The cancer selected from the group consisting of melanoma, breast cancer, colon cancer, lung cancer, and ovarian cancer.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: September 6, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole F. Steinmetz, Frank Alexander Veliz, Brylee David B. Tiu
  • Bacterial delivery vehicles comprising tracer nucleic acid sequences
    Patent number: 11421222
    Abstract: The present disclosure relates generally to genetically tagged bacterial delivery vehicles comprising unique tracer nucleic acid sequences (herein referred to as “tracers”) for use in detecting and/or quantitating the presence of two or more different said bacterial delivery vehicles within a mixture of vehicles. The present disclosure relates to methods wherein the bacterial delivery vehicles are detected through, for example, performance of multiple cycles of amplification using primers that bind to sequences within the unique tracer. Such methods can be advantageously used in quality control to detect and quantitate mixtures of bacterial delivery vehicles within a pharmaceutical composition.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: August 23, 2022
    Assignee: ELIGO BIOSCIENCE
    Inventors: Igor Stzepourginski, Daniel Garry
  • Binding agents to pre-fusion state SARS-CoV-2 spike protein
    Patent number: 11421019
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 23, 2022
    Inventors: Yang Xiang, Yan Tan
  • Membrane lipid coated viral nanoparticles and method of use
    Patent number: 11413252
    Abstract: Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells.
    Type: Grant
    Filed: April 21, 2018
    Date of Patent: August 16, 2022
    Assignee: Coastar Therapeutics Inc.
    Inventor: Eddie Yocon Chung
  • Oncolytic T7 bacteriophage having cytokine gene and displaying homing peptide on capsid and its use for treating melanoma
    Patent number: 11384338
    Abstract: Provided is an oncolytic recombinant bacteriophage T7 expressing a cytokine in eukaryotic cells and displaying on its capsid a tumor specific homing peptide, thus inducing direct lysis of target tumor cells and immunological response to the phage leading to the effective anticancer effect. The phage naturally infecting bacteria, not human beings, provides a great advantage for gene manipulation and production for the development of anticancer agents.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: July 12, 2022
    Assignee: ARKGEN BIOSCIONS CO., LTD
    Inventors: Heejoon Myung, Yoonjung Hwang
  • Compositions, methods and kits to detect adenovirus nucleic acid
    Patent number: 11384387
    Abstract: The disclosed disclosure is related to methods, compositions, and kits for targeting Adenovirus, nucleic acid. Compositions include amplification oligomers and/or detection probe oligomers. Kits and methods comprise at least one of these oligomers. Methods include uniplex and multiplex amplification and detection reactions.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: July 12, 2022
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Mehrdad R. Majlessi, Ankur Shah, Amber Hillius, Pamela Douglass, Daniel Kolk
  • Immunogenic and vaccine compositions against SARS-CoV-2
    Patent number: 11376320
    Abstract: Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: July 5, 2022
    Assignee: Iowa State University Research Foundation, Inc.
    Inventor: Michael Wan Cho
  • Anti-coronavirus antibodies and methods of use
    Patent number: 11370828
    Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: June 28, 2022
    Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.
    Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
  • Compositions and methods for modulating immune cells
    Patent number: 11369678
    Abstract: Disclosed herein are methods of modulation of the viability of a cell using fusion proteins comprising a transporter peptide sequence and a MYC polypeptide. Further disclosed herein are methods of modulating an immune response using the fusion proteins. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: June 28, 2022
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Methods of making anti-GP41 antibody-specific capture agents
    Patent number: 11365220
    Abstract: The present application provides stable peptide-based antibody capture agents and methods of use as detection and diagnosis agents. The application further provides methods of manufacturing antibody capture agents using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: June 21, 2022
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Jessica A. Pfeilsticker, Aiko Umeda, James R Heath
  • Enhanced promoter
    Patent number: 11352643
    Abstract: A new promoter comprising: (i) an hCMV enhancer sequence; (ii) an hCMV promoter sequence; (iii) a splice donor region; (iv) a cell-derived enhancer sequence; and (v) a splice acceptor region.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 7, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Stefano Colloca
  • bacteriophage Lac-GAP-3 and use thereof in inhibiting proliferation of bacteria
    Patent number: 11351210
    Abstract: The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcus garvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcus garvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: June 7, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang, Hyun Min Song, Sang Hyeon Kang
  • CMV-based intra-tumoral cancer therapies
    Patent number: 11351237
    Abstract: A CMV-based vaccine that promotes immune-mediated destruction of cancer through a onetime or repeated intratumoral administration of a recombinant CMV to generate a robust, long-lasting anti-tumor immune response.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: June 7, 2022
    Assignee: THOMAS JEFFERSON UNIVERSITY
    Inventors: Christopher M. Snyder, Daniel A. Erkes
  • Methods of treating bladder cancer with an oncolytic virus
    Patent number: 11338003
    Abstract: The present invention provides methods for treating an individual having bladder cancer comprising intravesically administering to the individual an oncolytic virus. Also provided are pharmaceutical compositions and kits for treating bladder cancer.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: May 24, 2022
    Assignee: CG ONCOLOGY, INC.
    Inventor: Arthur Kuan
  • Compositions and methods for activating antigen presenting cells with chimeric poliovirus
    Patent number: 11331343
    Abstract: Chimeric poliovirus is capable of activating antigen presenting cells. The activation of the antigen presenting cells may be in vitro, ex vivo, or in vivo. The activated antigen presenting cells may be administered alone or with an antigen or vaccine. The activated antigen may be loaded in vitro or ex vivo with antigen to form antigen-loaded, activated, antigen presenting cells. These may be administered therapeutically. Therapeutic administration of antigen presenting cells may be used as an adjuvant to other therapies.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 17, 2022
    Assignee: Duke University
    Inventors: Smita Nair, Michael Brown, Darell Bigner, Matthias Gromeier
  • Antibody purification method
    Patent number: 11332516
    Abstract: Disclosed are methods by which compounds/molecules capable of binding antigens, for example antibody type compounds/molecules, can be purified, extracted and/or selected. The methods may be used to purify, extract or select a specific type (or types) of binding agent from a mixed composition. The methods may be used to extract or purify specific binding agents from mixed compositions, which compositions comprise other agents capable of binding other antigens. The methods may find particular application as methods for the purification of blood group antigen antibodies.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: May 17, 2022
    Assignee: QBD (QS-IP) LIMITED
    Inventors: Neil Renault, Andrew Gordon Robb, Janine Scott Robb, David Cooper Robson
  • Bacteriophage compositions and methods of use thereof
    Patent number: 11311582
    Abstract: The present application provides bacteriophage compositions, and methods of treating or preventing bacterial infections using the bacteriophage compositions. The bacteriophage compositions can inhibit bacterial adhesion, invasion, and/or colonization in epithelial cells. The compositions and methods described herein are useful for treating or preventing mastitis in dairy cows.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: April 26, 2022
    Assignee: LOCUS BIOSCIENCES, INC.
    Inventors: Mike Paros, Ryan Honaker, Zachary Alan Hobbs, Manuela Richter, Lucia Mokres, Ermir Kadija
  • Methods of detecting influenza
    Patent number: 11306366
    Abstract: Compositions and methods for detecting influenza are provided.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: April 19, 2022
    Assignee: Cepheid
    Inventors: Anupama Mokkapati, Bradley Brown, Robert Jones